肾移植受者上尿路尿路上皮癌术后膀胱复发的预后因素

doi:10.3969/j.issn.1671-167X.2015.04.011

摘要/Abstract

摘要：

目的：评价肾输尿管全长切除术治疗肾移植受者原发上尿路尿路上皮癌（upper tract urothelial carcinoma，UTUC）术后膀胱复发的独立危险因素。方法：回顾2006年4月至2013年3月临床诊断为肾移植后局限性UTUC并且排除既往或同期合并膀胱肿瘤的病例共38例，均接受后腹腔镜下肾输尿管全长切除术。采用Kaplan-Meier方法对临床病理特征、危险因素和术后膀胱无复发生存率进行单因素分析。采用单因素和多因素Cox比例风险回归模型分析影响膀胱肿瘤复发的独立危险因素。结果：本组患者随访时间12~104个月，中位随访时间38个月，其间膀胱复发率42.1%（16/38），其中75.0%复发于术后2年内，手术与复发间隔时间6~48个月，中位复发时间15.5个月。单因素分析显示，原肾为马兜铃酸肾病（aristolochic acid nephropathy，AAN）、肿瘤为多中心和累及输尿管下段可增加膀胱复发风险。术后2年膀胱复发率，原肾AAN组为62.5%（5/8），肿瘤多中心发病组为46.2%（12/26）。多因素分析结果表明，肿瘤多中心发病（HR=2.603，95% CI=1.529~8.906，P=0.019）和原肾马兜铃酸肾病（HR=2.179，95% CI=1.085~8.093，P=0.038）是术后膀胱复发的独立预后危险因素。结论：肾移植受者UTUC经腹腔镜肾输尿管全长切除术后膀胱复发率高，大多数病例于术后2年内复发，多因素分析显示，肿瘤多中心发病和原肾AAN是术后膀胱复发的独立预后危险因素。

关键词: 泌尿道, 癌, 移行细胞, 膀胱肿瘤, 肿瘤复发, 局部, 肾移植

Abstract:

Objective：To elucidate clinicopathological independent prognostic factors for intravesical recurrence after nephroureterectomy for native upper tract urothelial carcinoma (UTUC) in renal transplant recipients. Methods: In this study, 38 patients clinically diagnosed as localized UTUC after renal transplantation were included, and treated by retroperitoneal laparoscopic nephroureterectomy between April 2006 and March 2013, after exclusion of those with a previous and/or concurrent history of bladder cancer. The clinicopathologic features, risk factors, and intravesical recurrence free survival were analyzed using the Kaplan-Meier method. Univariate and multivariate analyses by Cox’s proportional hazards regression model were used to identify independent risk factors for intravesical tumor recurrence. Results: Of all the patients, 16/38 (42.1%) developed subsequent intravesical recurrence during a median follow-up period of 38 months (range 12 to 104 months), of whom, 12/16 (75.0%) developed recurrent bladder cancer within 2 years after nephroureterectomy, and the median interval between surgery and intravesical recurrence was 15.5 months (range 6 to 48 months). Multifocal tumors, native aristolochic acid nephropathy (AAN) and distal ureter involvement were determined as risk factors for intravesical recurrence by univariate analysis. The intravesical recurrence rate was 62.5%(5/8) in the group of native AAN , and 46.2% (12/26) in the group of multifocality. By multivariate analyses, multifocality (HR=2.603, 95% CI=1.529-8.906, P=0.019) and native AAN (HR=2.179, 95% CI=1.085-8.093, P=0.038) were identified as independent predictors for the development of recurrent bladder cancer after surgery for UTUC in renal transplant recipients. Conclusion: The incidence of intravesical recurrence after laparoscopic nephroureterectomy for UTUC in renal transplant recipients is high, and most subsequent bladder cancers recur within 2 years after surgery. Tumor multifocality and native AAN are significant independent risk factors in developing initial intravesical recurrence after laparoscopic surgery for primary UTUC after renal transplantation.

Key words: Urinary tract, Carcinoma, transitional cell, Urinary bladder neoplasms, Neoplasm recurrence, local, Kidney transplantation

中图分类号:

R737.14

刘余庆, 卢剑, 赵磊, 侯小飞, 马潞林. 肾移植受者上尿路尿路上皮癌术后膀胱复发的预后因素[J]. 北京大学学报(医学版), 2015, 47(4): 605-610.

LIU Yu-Qing, LU Jian, ZHAO Lei, HOU Xiao-Fei, MA Lu-Lin. Prognostic factors for intravesical recurrence after surgery for upper tract urothelial carcinoma in renal transplant recipients[J]. Journal of Peking University(Health Sciences), 2015, 47(4): 605-610.

参考文献

相关文章 15

[1]	丁汉东, 王琴, 廖贵益, 郝宗耀. 肾移植术后并发消化道出血的诊治[J]. 北京大学学报（医学版）, 2024, 56(5): 902-907.
[2]	黄教悌,胡菁,韩博. 治疗相关神经内分泌前列腺癌机制研究与靶向治疗新进展[J]. 北京大学学报（医学版）, 2024, 56(4): 557-561.
[3]	张树栋,谢睿扬. 机器人手术时代的肾癌合并腔静脉瘤栓治疗策略[J]. 北京大学学报（医学版）, 2024, 56(4): 562-564.
[4]	邢念增,王明帅,杨飞亚,尹路,韩苏军. 前列腺免活检创新理念的临床实践及其应用前景[J]. 北京大学学报（医学版）, 2024, 56(4): 565-566.
[5]	欧俊永,倪坤明,马潞林,王国良,颜野,杨斌,李庚午,宋昊东,陆敏,叶剑飞,张树栋. 肌层浸润性膀胱癌合并中高危前列腺癌患者的预后因素[J]. 北京大学学报（医学版）, 2024, 56(4): 582-588.
[6]	颜野,李小龙,夏海缀,朱学华,张羽婷,张帆,刘可,刘承,马潞林. 前列腺癌根治术后远期膀胱过度活动症的危险因素[J]. 北京大学学报（医学版）, 2024, 56(4): 589-593.
[7]	于书慧,韩佳凝,钟丽君,陈聪语,肖云翔,黄燕波,杨洋,车新艳. 术前盆底肌电生理参数对前列腺癌根治性切除术后早期尿失禁的预测价值[J]. 北京大学学报（医学版）, 2024, 56(4): 594-599.
[8]	刘帅,刘磊,刘茁,张帆,马潞林,田晓军,侯小飞,王国良,赵磊,张树栋. 伴静脉癌栓的肾上腺皮质癌的临床治疗及预后[J]. 北京大学学报（医学版）, 2024, 56(4): 624-630.
[9]	杨文博,余磊,张维宇,徐涛,王强. 带线输尿管支架自排技术在肾移植受者中的效果及安全性[J]. 北京大学学报（医学版）, 2024, 56(4): 656-660.
[10]	舒帆,郝一昌,张展奕,邓绍晖,张洪宪,刘磊,王国良,田晓军,赵磊,马潞林,张树栋. 肾部分切除术治疗囊性肾癌的功能学和肿瘤学结果：单中心回顾性研究[J]. 北京大学学报（医学版）, 2024, 56(4): 667-672.
[11]	周泽臻,邓绍晖,颜野,张帆,郝一昌,葛力源,张洪宪,王国良,张树栋. 非转移性T_3a肾细胞癌患者3年肿瘤特异性生存期预测[J]. 北京大学学报（医学版）, 2024, 56(4): 673-679.
[12]	苏俊琪,王晓颖,孙志强. 舌鳞状细胞癌根治性切除术后患者预后预测列线图的构建与验证[J]. 北京大学学报（医学版）, 2024, 56(1): 120-130.
[13]	任晓萌,李凯一,李春蕾. 基于转录组测序探索口腔扁平苔藓局部激素治疗敏感性相关分子特征[J]. 北京大学学报（医学版）, 2024, 56(1): 32-38.
[14]	刘耘充,吴宗龙,葛力源,杜坦,吴雅倩,宋一萌,刘承,马潞林. 肾透明细胞癌中核蛋白1对阿昔替尼耐药的作用及机制[J]. 北京大学学报（医学版）, 2023, 55(5): 781-792.
[15]	刘欢锐,彭祥,李森林,苟欣. 基于HER-2相关基因构建风险模型用于膀胱癌生存预后评估[J]. 北京大学学报（医学版）, 2023, 55(5): 793-801.

Metrics

Viewed

Full text

Abstract

Cited

Shared

Discussed